Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis

Gerwin Huls*, Andre B. Mulder, Stefano Rosati, Arjan A. van de Loosdrecht, Edo Vellenga, Joost T. M. de Wolf

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

53 Citations (Scopus)

Abstract

Patients with refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) are difficult to treat because the cytoreductive treatment might be beneficial for the thrombocytosis component but harmful for the RARS component. As lenalidomide has shown to be efficacious in both myelodysplastic syndromes and myeloproliferative neoplasms, we have treated 2 RARS-T patients, who were transfusion dependent, with lenalidomide. We report the results of lenalidomide treatment in these patients and show that lenalidomide has clinical activity in this rare disorder. Both patients became transfusion independent, and 1 of the patients attained indeed a complete molecular remission. (Blood. 2010; 116(2): 180-182)

Original languageEnglish
Pages (from-to)180-182
Number of pages3
JournalBlood
Volume116
Issue number2
DOIs
Publication statusPublished - 15-Jul-2010

Keywords

  • MARKED THROMBOCYTOSIS
  • RARS-T
  • MYELODYSPLASTIC/MYELOPROLIFERATIVE DISEASE
  • MYELODYSPLASTIC SYNDROMES
  • FEATURES
  • DELETION
  • 5Q

Fingerprint

Dive into the research topics of 'Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis'. Together they form a unique fingerprint.

Cite this